Bloodstream infections occur when bacteria or fungi enter the bloodstream, potentially leading to severe systemic illness such as sepsis if not treated promptly.
BioVersys AG received FDA approval to enroll U.S. patients in a global Phase 3 trial evaluating BV100 for hospital-acquired pneumonia caused by carbapenem-resistant Acinetobacter baumannii, with trial completion expected by end of 2027.
The World Health Organization published blueprints for urgently needed antibiotics targeting drug-resistant infections, while CARB-X awarded $1.2 million for novel antibiotic research and the FDA issued guidance on antibiotic duration limits in livestock.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07408544 |
Clinical Efectiveness of a Multiplex PCR-Based Rapid Diagnostic Method in Bloodstream Infections |
RECRUITING | |
| NCT07172932 |
ANTIBIOTIC-RESISTANT ENTEROBACTERALES BLOODSTREAM INFECTIONS AND RISK FACTORS IN PATIENTS ADMITTED TO THE INTENSIVE CARE UNIT |
COMPLETED | |
| NCT06791889 |
Blood DdPCR for Early Identification and Dynamic Surveillance of Pathogenic Bacteria in ICU Septic Patients: a Single-centre, Prospective, Observational Study |
RECRUITING | |
| NCT06418048 |
INfectious DIsease REgistry BIObank |
RECRUITING | |
| NCT04156633 |
Clinical Impact of Rapid Identification of Positive Blood Cultures vs. Internal Laboratory Standard |
COMPLETED | |
| NCT03869437 |
RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI |
COMPLETED | PHASE2 |
| NCT02437045 |
Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response |
COMPLETED | PHASE4 |
| NCT02176122 |
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp. |
TERMINATED | PHASE4 |
| NCT01576003 |
Enteral Glutamine in Reducing Bloodstream Infections in Short Bowel Syndrome Infants |
COMPLETED | NA |
